title: Kinetics of plasma apolipoprotein C-III as a determinant of diet-induced changes in plasma triglyceride levels.
abstract: OBJECTIVE
  To compare the effect of a high monounsaturated fatty acid (MUFA) diet and of a control low-fat diet consumed under ad libitum conditions on plasma apolipoprotein (apo) C-III metabolism.
  
  
  METHODS
  Randomized, two-arm parallel dietary trial.
  
  
  METHODS
  Diets were prepared and consumed at the metabolic kitchen of the Department of Food Sciences and Nutrition, and laboratory analyses were performed at the Institute of Nutraceuticals and Functional Foods at Laval University.
  
  
  METHODS
  Eighteen men were randomly assigned to either the high MUFA diet or the low-fat control diet, which they consumed for 6-7 weeks. Before and after the dietary intervention, subjects received a primed-constant infusion of [5,5,5-D(3)]-L-leucine for 12 h under constant feeding conditions for the determination of plasma apoC-III kinetics.
  
  
  RESULTS
  The high-MUFA diet and the low-fat control diet had no significant impact on plasma apoC-III production rate (PR) or fractional catabolic rate. However, diet-induced variations in plasma apoCIII PR predicted the reduction in plasma triglycerides and apoC-III levels (r=0.85, P<0.01 and r=0.73, P<0.05, respectively) in the high MUFA group only.
  
  
  CONCLUSIONS
  These results suggest that the hypotriglyceridemic effect of a high-MUFA diet may be attributable in part to a reduced hepatic production of apoC-III.
  
  
  BACKGROUND
  This study was supported in part by an operating grant from the Canadian Institutes of Health Research (CIHR), and the Canada Research Chair in Nutrition and Cardiovascular Health (B Lamarche).
authors.affiliation: Department of Food Science and Nutrition, Institute of Nutraceuticals and Functional Foods, Laval University, Québec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Desroches
authors.forename: I L
authors.initials: IL
authors.lastname: Ruel
authors.forename: Y
authors.initials: Y
authors.lastname: Deshaies
authors.forename: M-E
authors.initials: ME
authors.lastname: Paradis
authors.forename: W R
authors.initials: WR
authors.lastname: Archer
authors.forename: P
authors.initials: P
authors.lastname: Couture
authors.forename: N
authors.initials: N
authors.lastname: Bergeron
authors.forename: B
authors.initials: B
authors.lastname: Lamarche
mesh_terms: D000328:Adult; D053305:Apolipoprotein C-III / Q000097:blood / Q000378:metabolism*; D003903:Deuterium; D018752:Diet, Fat-Restricted; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007930:Leucine / Q000493:pharmacokinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D014280:Triglycerides / Q000097:blood*
chemical_list: D053305:Apolipoprotein C-III; D005229:Fatty Acids, Monounsaturated; D014280:Triglycerides; D003903:Deuterium; D007930:Leucine